Who Exports Salbutamol from India — 602 Suppliers Behind a $148.8M Market
India's salbutamol export market is supplied by 602 active exporters who collectively shipped $148.8M across 14,359 shipments. CIPLA LIMITED leads with a 67.4% market share, followed by GLENMARK PHARMACEUTICALS LIMITED and AHLCON PARENTERALS (INDIA) LIMITED. The top 5 suppliers together control 79.6% of total export value, reflecting a concentrated market structure.
Top Salbutamol Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading salbutamol exporter from India, holding a 67.4% share of the $148.8M market across 14,359 shipments from 602 exporters. The top 5 suppliers — CIPLA LIMITED, GLENMARK PHARMACEUTICALS LIMITED, AHLCON PARENTERALS (INDIA) LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED, FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED — collectively control 79.6% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (67.4%), GLENMARK PHARMACEUTICALS LIMITED (3.9%), AHLCON PARENTERALS (INDIA) LIMITED (3.3%), MEDISPRAY LABORATORIES PRIVATE LIMITED (3.3%), FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED (1.7%).
Top Salbutamol Exporters from India
Ranked by export value · 602 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $100.3M | 41 | 67.4% |
| 2 | GLENMARK PHARMACEUTICALS LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $5.7M | 11 | 3.9% |
| 3 | AHLCON PARENTERALS (INDIA) LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $4.9M | 4 | 3.3% |
| 4 | MEDISPRAY LABORATORIES PRIVATE LIMITED ASTHALIN 100 MCG INHALER (SALBUTAMOL SULASTHALIN 100MCG INHALERSALBUMED 100 MCG HFA INHALER (SALBUTAMOL | $4.9M | 2 | 3.3% |
| 5 | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED SALBUTAMOL TABLETS BP 4MG (49ASTHALIN 400 DP CAPS .ASTHALIN 400 DP CAPS (SALBUTAMOL SULPHAT | $2.6M | 5 | 1.7% |
| 6 | EMCURE PHARMACEUTICALS LIMITED | $2.2M | 14 | 1.5% |
| 7 | AMANTA HEALTHCARE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLAERO-VENT ( SALBUTAMOL SULPHATE RESPULESSALBUTAMOL 1MG/ML SOLUTION FOR INHALATION-AERO-VENT | $2.0M | 4 | 1.3% |
| 8 | MGRM MEDICARE PRIVATE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLAERO-VENT ( SALBUTAMOL SULPHATE RESPULESSALBUTAMOL 1MG/ML SOLUTION FOR INHALATION-AERO-VENT | $1.8M | 1 | 1.2% |
| 9 | CHANDRA BHAGAT PHARMA PRIVATE LIMITED ASTHARIX INHALER SALBUTAMOL AS SULFATEASTHAVENT HFA INHALER | $1.4M | 1 | 0.9% |
| 10 | MACLEODS PHARMACEUTICALS LTD DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $1.3M | 20 | 0.9% |
| 11 | AGIO PHARMACEUTICALS LIMITED | $1.2M | 5 | 0.8% |
| 12 | ALTHEA PHARMA PRIVATE LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLAERO-VENT ( SALBUTAMOL SULPHATE RESPULESSALBUTAMOL 1MG/ML SOLUTION FOR INHALATION-AERO-VENT | $1.2M | 1 | 0.8% |
| 13 | MANCARE PHARMACEUTICALS PRIVATE LIMITED | $989.0K | 1 | 0.7% |
| 14 | AHLCON PARENTERALS INDIA LIMITED DUOLIN RESPULES 2.5ML RESPULES) [17280X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [17136X12X5'S]DUOLIN RESPULES 2.5ML RESPULES) [15600X12X5'S] | $967.2K | 1 | 0.7% |
| 15 | ZYDUS LIFESCIENCES LIMITED SALBUTAMOL & IPRATROPIUM BROMIDE RESPIRATOR SOLUTION 2.5MLAERO-VENT ( SALBUTAMOL SULPHATE RESPULESSALBUTAMOL 1MG/ML SOLUTION FOR INHALATION-AERO-VENT | $730.9K | 5 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Salbutamol exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla is a leading Indian pharmaceutical company with multiple FDA approvals and |
| GLENMARK PHARMACEUTICALS LIMITED | Warning Letter, July 2025 | Yes | Yes | Multiple | Received FDA warning letter in July 2025 for Madhya Pradesh facility; holds WHO- |
| EMCURE PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Emcure has FDA approvals and holds WHO-GMP and EU-GMP certifications. |
| MACLEODS PHARMACEUTICALS LTD | Approved | Yes | Yes | Multiple | Macleods Pharmaceuticals is FDA-approved and holds WHO-GMP and EU-GMP certificat |
| FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED | Not Listed | Yes | Yes | Not verified | Fourrts holds WHO-GMP and EU-GMP certifications; FDA status not listed. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | Multiple | Zydus Lifesciences has FDA approvals and holds WHO-GMP and EU-GMP certifications |
| MICRO LABS LIMITED | Approved | Yes | Yes | Multiple | Micro Labs is FDA-approved and holds WHO-GMP and EU-GMP certifications. |
| GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED | Warning Letter, October 2 | Yes | Yes | Not verified | Received FDA warning letter in October 2023 for Tamil Nadu facility; holds WHO-G |
TransData Nexus reviewed the regulatory standing of 8 leading Salbutamol exporters from India. 5 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Salbutamol sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of active pharmaceutical ingredients (APIs). The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's capabilities in research and development, particularly in APIs and biologics.
The Telangana government's initiative to develop "Pharma City" aims to create the world's largest integrated pharmaceutical cluster, consolidating manufacturing, research, and support services. This development is expected to bolster Hyderabad's position as a leading center for API production, including Salbutamol.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's well-established infrastructure, including ports and transportation networks, facilitates efficient manufacturing and distribution of pharmaceutical products.
The state's emphasis on regulatory compliance and quality standards makes it a preferred location for the production of finished dosage forms, including Salbutamol tablets and inhalers. The presence of a skilled workforce and supportive government policies further enhance the region's attractiveness for pharmaceutical manufacturing.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, provides access to international markets and regulatory bodies. The region hosts numerous pharmaceutical companies with a strong focus on both API and formulation manufacturing.
The proximity to major ports and airports facilitates the efficient export of pharmaceutical products, including Salbutamol, to global markets. The region's well-developed infrastructure and connectivity make it a strategic location for companies aiming to expand their international footprint.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as significant pharmaceutical manufacturing hubs, primarily due to favorable tax incentives and government policies. Baddi is home to over 1,000 pharmaceutical manufacturing units, making it one of the largest pharmaceutical hubs in Asia. The region's strategic location and supportive infrastructure have attracted numerous companies specializing in the production of various pharmaceutical products, including Salbutamol.
5Sourcing Recommendations
- Diversify Supplier Base: While CIPLA LIMITED dominates Salbutamol exports with a 67.4% share, consider engaging with other manufacturers to mitigate supply chain risks.
- Evaluate Regional Strengths: Leverage the specific strengths of each pharmaceutical cluster. For instance, source APIs from Hyderabad and formulations from the Ahmedabad-Vadodara region to optimize quality and cost.
- Assess Export Logistics: Utilize the Mumbai-Thane-Raigad region's infrastructure for efficient export operations, ensuring timely delivery to international markets.
- Monitor Regulatory Compliance: Ensure that all suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
By strategically sourcing from India's specialized pharmaceutical clusters, companies can enhance their supply chain resilience and meet global demand for Salbutamol effectively.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Salbutamol exporters from India
Cipla Limited — Cipla acquires Ivia Beaute's cosmetics and personal care business
Cipla Limited acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore. - IMPACT: This acquisition is not expected to directly impact Cipla's Salbutamol exports.
Impact: This acquisition is not expected to directly impact Cipla's Salbutamol exports.
Cipla Limited — Cipla acquires 21.05% stake in Achira Labs
Cipla Limited acquired a 21.05% stake in Achira Labs Private Limited, a company specializing in medical diagnostics. - IMPACT: This investment is not anticipated to have a direct effect on Cipla's Salbutamol export activities.
Impact: This investment is not anticipated to have a direct effect on Cipla's Salbutamol export activities.
Cipla Limited — Cipla forms joint venture Aspergen Inc.
Cipla (EU) Limited, a subsidiary of Cipla Limited, entered into a 60:40 joint venture with Kemwell Biopharma UK Limited to form Aspergen Inc., USA. - IMPACT: This joint venture is not expected to directly influence Cipla's Salbutamol export operations.
Impact: This joint venture is not expected to directly influence Cipla's Salbutamol export operations.
Common Questions — Salbutamol Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which salbutamol supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 2,828 recorded shipments worth $100.3M. GLENMARK PHARMACEUTICALS LIMITED (298 shipments) and AHLCON PARENTERALS (INDIA) LIMITED (117 shipments) are also established high-volume exporters.
Q How many salbutamol manufacturers are there in India?
India has 602 active salbutamol exporters with a combined export market of $148.8M across 14,359 shipments to 164 countries. The top 5 suppliers hold 79.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for salbutamol from India?
Average FOB unit price: $2.56 per unit, ranging from $0.00 to $11607.35. Average shipment value: $10.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 602 verified Indian exporters of Salbutamol ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 14,359 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 164 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
14,359 Verified Shipments
602 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists